You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

December 2, 2024

Thailand’s Updated Guidelines on Kratom in Food and Herbal Products

Subscribe to Updates

Kratom (Mitragyna speciosa) was once listed as a prohibited substance under the Narcotics Act. Kratom was then removed from the narcotics list in 2021 and is now regulated under the Kratom Plant Act B.E. 2565 (2022), which allows the trading, use, import, and export of kratom. Furthermore, the Ministry of Public Health has allowed the use of kratom in food and drink, food supplements, and herbal products. Anyone who wishes to launch kratom food or herbal products must first obtain a product license from the Thai Food and Drug Administration (FDA).

On September 4, 2024, the Thai FDA announced guidelines specifically for powdered kratom leaves and kratom leaf extracts (using water or ethanol as solvents) as ingredients in food supplements. These guidelines aim to provide business operators with a clear framework for launching kratom-based food products in Thailand.

Key points from these guidelines include:

  • Raw material specifications and standards: Powdered kratom leaves and kratom leaf extracts must contain at least the prescribed amount of mitragynine (one of the primary active compounds in kratom) as a marker of quality. For example, mitragynine must account for at least 1% by mass for powdered kratom leaves.
  • Food supplement specification and standards: Food supplements containing powdered kratom leaves or kratom leaf extracts must not have a dosage of over 0.2 mg/day of mitragynine (including 7-hydroxymitraglynine, which may occur naturally), or 1 mg/day for food supplements containing kratom extracts that use water as a solvent. Addition of 7-hydroxymitraglynine to food supplements is prohibited.

    Mitragynine content in food supplement products must not exceed the specified dosage limit. Additionally, the food supplement product must be in a ready-to-eat form (e.g., liquid, gel, tablet, or capsule).

    If powdered kratom leaves or kratom leaf extracts are to be used as ingredients in food categories other than food supplements, a safety assessment must be conducted prior to their use, ensuring compliance with the necessary health and safety standards.

  • Manufacturing practices: The manufacturing locations of dietary supplements containing Kratom must comply with good manufacturing practice (GMP) standards, as specified in the annex to the Ministry of Public Health Announcement (No. 420) B.E. 2563 (2020) Re: Food Production Processes, Processing Equipment/Utensils and Storage Practices.
  • Labeling and warning statements: The labels of food supplements containing powdered kratom leaves or kratom leaf extracts must comply with the Notification of the Ministry of Public Health Re: Labeling and Food Supplement Products. The labels must also display the following warning statements:
    • Must not be consumed continuously for more than seven days.
    • Do not use this product in conjunction with other products containing kratom.
    • Must not be consumed with products containing alcohol.

    Additionally, there must be statements regarding prohibited usage for high-risk consumers. For example, products must not be used in patients with cardiovascular diseases, diabetes, or psychiatric disorders.

  • Approval process: Requests for approval of food supplement products containing powdered kratom leaves and kratom leaf extracts can be submitted online through the Thai FDA’s e-submission system. Submissions must include the product specifications, standards, and conditions of use in accordance with the established guidelines. Additionally, a laboratory report detailing the mitragynine content must be provided to the Thai FDA during the product registration process. If the product is imported, a certificate on the food standards of the manufacturing practices of the overseas manufacturer must be provided as part of the registration process.

Kratom as an Herbal Product
In addition to food products, kratom can also be approved as an herbal product under the Thai FDA’s Herbal Product Division. The requirements for registering kratom products as herbal products are distinct and include:

  • Herbal product specifications and standards: Kratom used in herbal products must adhere to strict quality and purity standards. This includes thorough testing for contaminants and verification of active ingredient concentrations. These stringent requirements ensure the safety and efficacy of kratom herbal products for consumers.

    The Herbal Product Division also provides guidelines for the registration of kratom leaf concentrates extracted using water and kratom leaf aqueous solutions. The guidelines specify that the amount of mitragynine must not exceed one milligram per day.

  • Manufacturing practices: Producers must adhere to good manufacturing practices (GMP) to ensure the consistency, safety, and efficacy of the herbal products. For importers, the manufacturing site is required to obtain GMP clearance verifying the standards of the overseas manufacturer, which must be equivalent or greater than the GMP standards in Thailand.
  • Labeling, leaflets, and packaging: Herbal products must have clear and informative labels that include dosage instructions, potential side effects, and contraindications. Kratom product labels and leaflets must have additional warnings or precautions as required to ensure the safety of the kratom usage. For instance, kratom products classified as herbal products for health promotion must display additional warning statements similar to the statements for food supplements mentioned above. Additionally, leaflets must contain contraindications to avoid safety issues, such as prohibiting the use of kratom products in people taking anticoagulants. These statements must comply with the guidelines issued by the Herbal Product Division.
  • Approval process: The approval process for herbal products involves submitting an application that includes product samples, safety data, and evidence of efficacy to the Herbal Product Division. The submitted documents must demonstrate that the products are safe for use and must provide evidence of the claimed health benefits.

Market Implications

The approval of kratom as a food or herbal product presents significant opportunities for both local and international producers. In Thailand, the number of approved kratom products remains relatively low, indicating substantial room for market expansion. Businesses can now legally cultivate, produce, and sell kratom if they adhere to the regulatory standards set by the Thai FDA. This regulatory clarity is anticipated to stimulate growth in the kratom market in terms of both domestic sales and export potential.

For further information on Thailand’s laws and regulations on kratom products, please contact Dr. Atthachai Homhuan at [email protected], Ravi Pinkoh at [email protected], or Sonatree Sehamontree at [email protected].

Related Professionals

Industries

Life Sciences

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

July 24, 2026
For businesses in Thailand’s regulated industries, the problem of “too many licenses” is one of the most familiar hurdles to getting a product to market. Take a simple example: importing the materials necessary to sell teriyaki chicken skewers. To legally do this, a business may need approvals from several different agencies—separate permits for the chicken (Department of Livestock Development), the dipping sauce (Thai FDA), the wooden skewers (Department of Forestry), and other ingredients, each under a different authority. This kind of overlap is often cited to argue for a “regulatory guillotine”—a systematic review to cut outdated or duplicative rules that slow investment and business activity. The Facilitation of Licensing and Public Service Consideration Act B.E. 2569 (2026) (Licensing Facilitation Act 2026) is Thailand’s most significant response yet to that concern. This article looks at the Facilitation Act 2026 through a life sciences and regulatory affairs lens—what it may mean for the manufacturers, importers, and distributors of food, drugs, medical devices, cosmetics, and similar products who routinely deal with several regulators to bring a single product to market. The Super License: One Approval Standing in for Many The reform with the clearest potential for regulated-product businesses is the law’s “super license” mechanism, referred to as a “main license” in the statute. Once a business obtains the main license for a regulated activity, it is automatically deemed to hold all related sublicenses issued by other agencies for that same activity, provided the activity has been designated as eligible in the Government Gazette. The Licensing Facilitation Act 2026 also creates a central application center, allowing applicants to submit a single application and pay all relevant fees at one point of contact, with the center routing the application to each agency through a shared information system. The potential benefits of this for businesses
Read More
July 13, 2026
Indonesia’s Halal Product Assurance Agency (BPJPH) has issued new regulations establishing clearer procedures for imposing administrative sanctions on businesses that violate halal product assurance requirements. BPJPH Regulation No. 2 of 2026 on the Imposition of Administrative Sanctions for Violations of Halal Product Assurance Implementation, issued on June 5, 2026, strengthens Indonesia’s halal compliance framework, as mandated under Law No. 33 of 2014 on Halal Product Assurance and Government Regulation No. 42 of 2024 on the Implementation of Halal Product Assurance. BPJPH Regulation No. 2/2026 also supports the upcoming mandatory halal compliance deadline of October 17, 2026, which will apply to a broad range of products and services, including imported food and beverages, slaughtering products and services, natural and quasi-drugs, health supplements, cosmetics, chemical and genetically engineered products, clothing and accessories, household goods, prayer equipment, stationery, and class A medical devices. Scope BPJPH is authorized to impose administrative sanctions for violations of halal product assurance requirements committed by businesses, halal inspection agencies (LPH), halal auditors, halal product process companion institutions (lembaga pendamping PPH), and halal product process companions (pendamping PPH). The head of BPJPH has authority to determine, cancel, or amend the imposition of administrative sanctions, including upon receipt of objections. This authority covers revocation of Halal Certificates (including foreign halal certificate registration numbers), withdrawal of goods from circulation, freezing of LPH operations, freezing of halal product process companion institutions, revocation of PPH companion institution registration numbers, revocation of halal auditor registration numbers, and revocation of LPH accreditation status. Administrative Sanctions Businesses may be subject to any of the following administrative sanctions: Written warning; Administrative fine; Revocation of the halal certificate, including revocation of foreign halal certificate registration numbers; and Withdrawal of goods from circulation. The regulation sets out the types of violations that may trigger these sanctions, with each
Read More
July 1, 2026
Obtaining marketing authorization is a fundamental requirement for bringing pharmaceutical products to the Thai market. Companies must navigate the Thai Food and Drug Administration’s registration procedures while also complying with post-approval pharmacovigilance obligations, licensing requirements for manufacturing and importation, data protection rules, and other regulatory requirements. This guide provides an overview of Thailand’s regulatory framework for pharmaceutical marketing authorization, including available registration pathways, review timelines, application fees, postmarketing surveillance obligations, licensing requirements, exemptions, data exclusivity, freedom of information, and parallel import considerations. It is intended as a practical reference for pharmaceutical companies, regulatory affairs professionals, and others involved in bringing medicinal products to the Thai market. Download the guide below for a concise overview of the current requirements and procedures governing pharmaceutical marketing authorization in Thailand.
Read More
June 24, 2026
Patent enablement requirements are provided under Article 102 of Vietnam’s Law on Intellectual Property (IP Law). In particular, a patent specification must “fully and clearly disclose the nature of the invention to such an extent that, based on the specification, a person having ordinary skill in the relevant art can implement the invention.” In pharmaceutical and biotechnology patents, this requirement is more complicated and subject to more rigorous assessment. The Patent Examination Guidelines (Guidelines) of the Intellectual Property Office of Vietnam (IP Office) were amended in March 2026 to introduce Annexes III and IV for the pharmaceutical and biotechnology sectors, in which Annex III provides detailed guidelines on the assessment of specification requirements. These amendments were made under a project for strengthening capacity in industrial property examination between the Japan International Cooperation Agency (JICA) and the IP Office. Annex III provides detailed instructions on how examiners assess enablement in a pharmaceutical or biotechnology application, and offers examples of acceptable and unacceptable descriptions with regard to the enablement aspect. Enablement Requirements in Pharma and Biotech Patents Article 12.7 of Circular 10/2026/TT-BKHCN (Circular 10) adds to the requirements of Article 102 of the IP Law that the description must demonstrate the novelty, inventive step, and industrial applicability of the technical solution. For pharmaceutical composition subject matters, Article 12.9 of Circular 10 sets out that the description must present the results of clinical trials and/or the pharmacological effects of the claimed pharmaceutical composition, and must include at least the following information: Substance/mixture used. Testing method (system) employed. Information on the test results. Correlation between the pharmacological effects obtained from the tests and the application of the pharmaceutical product in the prevention, diagnosis, and treatment of diseases. The Guidelines note that pharmacological study results should be presented in a quantified manner, and pharmacological
Read More